No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
LLY241220C832500
- 4.14
- +0.16+4.02%
15min DelayClose Dec 13 16:00 ET
4.65High3.55Low
4.60Open3.98Pre Close23 Volume21 Open Interest832.50Strike Price9.37KTurnover50.59%IV6.02%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry4.14Extrinsic Value100Contract SizeAmericanOptions Type0.1785Delta0.0059Gamma190.15Leverage Ratio-1.3087Theta0.0167Rho33.95Eff Leverage0.2273Vega
Intraday
- 5D
- Daily
News
Eli Lilly and Co's blockbuster new drug "Tirzepatide" has filed its fifth marketing application in China.
On December 14, the latest announcement on the CDE website states that Eli Lilly and Co (LLY.US) has had its new indication application for the blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection accepted.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) have reached a commercialization agreement for "Jepalin" in mainland China.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a collaboration agreement regarding the rights of Eli Lilly’s non-covalent (reversible) BTK inhibitor "Jehpaili" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sale, promotion, and distribution of Jehpaili, while Eli Lilly will be responsible for the research and development and post-marketing medical affairs related work for Jehpaili. INNOVENT BIO's founder, Chairman and CEO Yu Dechao expressed great pleasure in further deepening the strategic cooperation with Eli Lilly, noting that Jehpaili is the latest generation, the first and only globally approved non-covalent (reversible) BTK inhibitor.
INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.
On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.
Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50